Consultations and Updates to the List

As per the Health (Pricing and Supply of Medical Goods) Act 2013, the HPRA is required to consult with relevant marketing authorisation holders prior to adding a medicine or a group of medicines to the list of interchangeable medicines. 

Full details on the general consultation process and the possible outcomes are provided in the Guide to Interchangeable Medicines.

Since the implementation of the legislation in 2013, the HPRA has been directed by the Department of Health or HSE to assess the interchangeability of specified active substances.

Details of ongoing and completed consultations, and resulting updates to the list of interchangeable medicines, are provided below:

Ongoing Consultations

Please note that the HPRA cannot comment or provide any further information on specific consultations.   

Isotretinoin: The review consultation process for Isotretinoin with the relevant marketing authorisation holders has commenced. It will conclude on 09 July 2024. The date of publication will be decided thereafter.

Irbesartan/Hydrochlorothiazide: The review consultation process for Irbesartan/Hydrochlorothiazide with the relevant marketing authorisation holders has commenced. It will conclude on 09 July 2024. The date of publication will be decided thereafter.

Irbesartan: The review consultation process for Irbesartan with the relevant marketing authorisation holders has commenced. It will conclude on 09 July 2024. The date of publication will be decided thereafter.

Rivastigmine: The review consultation process for Rivastigmine with the relevant marketing authorisation holders has commenced. It will conclude on 02 July 2024. The date of publication will be decided thereafter.

Trazodone: 
The review consultation process for Trazodone with the relevant marketing authorisation holders has commenced. It will conclude on 04 June 2024. The date of publication will be decided thereafter.

Amlodipine: The review consultation process for Amlodipine with the relevant marketing authorisation holders has commenced. It will conclude on 28 March 2017. The date of publication will be decided thereafter.

Perindopril: The review consultation process for Perindopril with the relevant marketing authorisation holders has commenced. It will conclude on 13 January 2015. The date of publication will be decided thereafter.

Acetylsalicylic acid: The consultation process for Acetylsalicylic acid with the relevant marketing authorisation holders has commenced. It will conclude on 05 June 2014. The date of publication will be decided thereafter.​


Completed Consultations

Desloratadine: The consultation process for Desloratadine with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Desloratadine medicines, was published on 23 June 2024.

Ulipristal: 
The consultation process for Ulipristal with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Ulipristal medicines, was published on 23 June 2024.

Celecoxib: 
The consultation process for Celecoxib with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Celecoxib medicines, was published on 23 June 2024.

Pramipexole: The consultation process for Pramipexole with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Pramipexole medicines, was published on 18 June 2024.

Fluconazole: The consultation process for Fluconazole with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Fluconazole medicines, was published on 11 June 2024.

Terbinafine: The consultation process for Terbinafine with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Terbinafine medicines, was published on 11 June 2024.

Icatibant: The consultation process for Icatibant with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Icatibant medicines, was published on 11 June 2024.

Sunitininb: 
The consultation process for Sunitinib with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Sunitinib medicines, was published on 28 May 2024.

Voriconazole: The consultation process for Voriconazole with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Voriconazole medicines, was published on 28 May 2024.

Ivabradine: The consultation process for Ivabradine with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Ivabradine medicines, was published on 28 May 2024.

Allopurinol: The consultation process for Allopurinol with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Allopurinol medicines, was published on 28 May 2024.

Ibandronic acid:
The consultation process for Ibandronic acid with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Ibandronic acid medicines, was published on 21 May 2024.

Exemestane: 
The consultation process for Exemestane with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Exemestane medicines, was published on 30 April 2024.

Sumatriptan: The consultation process for Sumatriptan with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Sumatriptan medicines, was published on 30 April 2024.

Dutasteride: 
The consultation process for Dutasteride with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Dutasteride medicines, was published on 16 April 2024.

Ibandronic acid: The consultation process for Ibandronic acid with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Ibandronic acid medicines, was published on 16 April 2024.

Salmeterol/Fluticasone: The consultation process for Salmeterol/Fluticasone with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Salmeterol/Fluticasone medicines, was published on 03 April 2024.

Modafinil: The consultation process for Modafinil with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Modafinil medicines, was published on 26 March 2024.

Fesoterodine: The consultation process for Fesoterodine with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Fesoterodine medicines, was published on 26 March 2024.

Lenalidomide: The consultation process for Lenalidomide with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Lenalidomide medicines, was published on 21 March 2024.

Bicalutamide: 
The consultation process for Bicalutamide with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Bicalutamide medicines, was published on 12 March 2024.

Apixaban: The consultation process for Apixaban with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Apixaban medicines, was published on 06 March 2024.

Sildenafil: 
The consultation process for Sildenafil with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Sildenafil medicines, was published on 06 March 2024.

Agomelatine
: The consultation process for Agomelatine with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Agomelatine medicines, was published on 04 March 2024.

Ipratropium bromide/salbutamol: 
The consultation process for Ipratropium bromide/salbutamol
with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Ipratropium bromide/salbutamol medicines, was published on 28 February 2024.

Escitalopram: 
The consultation process for Escitalopram with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Escitalopram medicines, was published on 28 February 2024.

Ezetimibe/Atorvastatin: 
The consultation process for Ezetimibe/Atorvastatin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Ezetimibe/Atorvastatin medicines, was published on 20 February 2024.

Zolpidem: The consultation process for Zolpidem with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Zolpidem medicines, was published on 19 February 2024.

Cinacalcet: The consultation process for Cinacalcet with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Cinacalcet medicines, was published on 26 January 2024.

Deferasirox: The consultation process for Deferasirox with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Deferasirox medicines, was published on 15 January 2024.

Paliperidone: The consultation process for Paliperidone with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Paliperidone medicines, was published on 15 January 2024.

Valaciclovir: The consultation process for Valaciclovir with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Valaciclovir medicines, was published on 10 January 2024.

Sitagliptin: The consultation process for Sitagliptin with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Sitagliptin medicines, was published on 21 December 2023.

Fulvestrant: 
The consultation process for Fulvestrant with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Fulvestrant medicines, was published on 21 December 2023.

Risperidone: 
The consultation process for Risperidone with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Risperidone medicines, was published on 13 December 2023.

Salbutamol: 
The consultation process for Salbutamol with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Salbutamol medicines, was published on 12 December 2023.

Solifenacin succinate/Tamsulosin: The consultation process for Solifenacin succinate/Tamsulosin
with the relevant marketing authorisation holders has been completed. The amended list, including  interchangeable Solifenacin succinate/Tamsulosin medicines, was published on 12 December 2023.

Duloxetine: The consultation process for Duloxetine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Duloxetine medicines, was published on 12 December 2023.

Posaconazole: 
The consultation process for Posaconazole with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Posaconazole medicines, was published on 22 November 2023.

Sertraline: 
The consultation process for Sertraline with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Sertraline medicines, was published on 22 November 2023.

Venlafaxine: 
The consultation process for Venlafaxine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Venlafaxine medicines, was published on 22 November 2023.

Lercanidipine: 
The consultation process for Lercanidipine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Lercanidipine medicines, was published on 22 November 2023.

Esomeprazole: 
The consultation process for Esomeprazole with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Esomeprazole medicines, was published on 22 November 2023.

Apixaban:
The consultation process for Apixaban with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Apixaban  medicines, was published on 08 November 2023.

Pirfenidone: 
The consultation process for Pirfenidone with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Pirfenidone medicines, was published on 27 October 2023.

Levetiracetam: The consultation process for Levetiracetam with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Levetiracetam medicines, was published on 17 October 2023.

Escitalopram: The consultation process for Escitalopram with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Escitalopram medicines, was published on 17 October 2023.

Dutasteride/TamsulosinThe consultation process for Dutasteride/Tamsulosin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Dutasteride/Tamsulosin medicines, was published on 26 September 2023.

Atorvastatin: The consultation process for Atorvastatin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Atorvastatin medicines, was published on 26 September 2023.

Bisoprolol: The consultation process for Bisoprolol with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Bisoprolol medicines, was published on 13 September 2023.

Flucloxacillin: 
The consultation process for Flucloxacillin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Flucloxacillin medicines, was published on 19 July 2023.

Losartan/Hydrochlorothiazide: 
The consultation process for Losartan/Hydrochlorothiazide with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Losartan/Hydrochlorothiazide
medicines, was published on 13 July 2023.

Abiraterone: 
The consultation process for Abiraterone with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Abiraterone medicines, was published on 12 July 2023.

Rosuvastatin/Ezetimibe: 
The consultation process for Rosuvastatin/Ezetimibe with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Rosuvastatin/Ezetimibe medicines, was published on 11 July 2023.

Midodrine: 
The consultation process for Midodrine with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Midodrine
medicines, was published on 04 July 2023.

Sertraline: The consultation process for Sertraline with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Sertraline medicines, was published on 27 June 2023.

Duloxetine: The consultation process for Duloxetine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Duloxetine medicines, was published on 27 June 2023.

Hydroxocobalamin: The consultation process for Hydroxocobalamin with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Hydroxocobalamin medicines, was published on 07 June 2023.

Atorvastatin: The consultation process for process for Atorvastatin with the relevant marketing  authorisation holders has been completed. The amended list, including interchangeable Atorvastatin medicines, was published on 23 May 2023.

Prucalopride: The consultation process for Prucalopride with the relevant marketing  authorisation holders has been completed. The amended list, including interchangeable Prucalopride medicines, was published on 25 April 2023.

Zopiclone: 
The consultation process for Zopiclone with the relevant marketing  authorisation holders has been completed. The amended list, including interchangeable Zopiclone medicines, was published on 28 March 2023.

Esomeprazole: 
The consultation process for Esomeprazole with the relevant marketing  authorisation holders has been completed. The amended list, including interchangeable Esomeprazole medicines, was published on 28 March 2023.

Pregabalin:
The consultation process for Pregabalin with the relevant marketing  authorisation holders has been completed. The amended list, including interchangeable Pregabalin medicines, was published on 11 January 2023.

Gabapentin:
The consultation process for Gabapentin with the relevant marketing  authorisation holders has been completed. The amended list, including interchangeable Gabapentin medicines, was published on 11 January 2023.

Metformin: 
The consultation process for Metformin with the relevant marketing  authorisation holders has been completed. The amended list, including interchangeable Metformin medicines, was published on 23 November 2022.

Rosuvastatin: 
The consultation process for Rosuvastatin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Rosuvastatin
medicines, was published on 29 September 2022.

Nebivolol: The consultation process for Nebivolol with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Nebivolol
medicines, was published on 29 September 2022.

Cetirizine: The consultation process for Cetirizine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Cetirizine
medicines, was published on 21 September 2022.

Valsartan: The consultation process for Valsartan with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Valsartan medicines, was published on 06 September 2022.

LatanoprostThe consultation process for Latanoprost with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Latanoprost
medicines, was published on 03 August 2022.

EzetimibeThe consultation process for Ezetimibe with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Ezetimibe 
medicines, was published on 03 August 2022.

Levetiracetam: The consultation process for Levetiracetam with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Levetiracetam medicines, was published on 28 June 2022.

Ondansetron:
 The consultation process for Ondansetron with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Ondansetron  medicines, was published on 28 June 2022.

Paroxetine: The consultation process for Paroxetine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Paroxetine  medicines, was published on 28 June 2022.

Pregabalin: The consultation process for Pregabalin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Pregabalin medicines, was published on 28 June 2022.

Lercanidipine: The consultation process for Lercanidipine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Lercanidipine medicines, was published on 28 June 2022.

Betahistine: The consultation process for Betahistine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Betahistine medicines, was published on 05 May 2022.

Omeprazole: The consultation process for Omeprazole with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Omeprazole medicines, was published on 20 April 2022.

Rosuvastatin/Ezetimibe: The consultation process for Rosuvastatin/Ezetimibe with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Rosuvastatin/Ezetimibe medicines, was published on 20 April 2022. 

Doxazosin: The consultation process for Doxazosin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Doxazosin medicines, was published on 22 March 2022.

Metformin: The consultation process for Metformin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Metformin medicines, was published on 08 March 2022.
 

Atorvastatin: The consultation process for Atorvastatin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Atorvastatin medicines, was published on 01 March 2022.

Tramadol/Dexketoprofen: The consultation process for Tramadol/Dexketoprofen with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Tramadol/Dexketoprofen medicines, was published on 01 March 2022.

 
Montelukast: The consultation process for Montelukast with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Montelukast medicines, was published on 08 February 2022.

Quetiapine: The consultation process for Quetiapine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Quetiapine medicines, was published on 08 February 2022.

Diclofenac Sodium: The consultation process for Diclofenac Sodium with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Diclofenac Sodium medicines, was published on 27 June 2023.

 
Valsartan: The consultation process for Valsartan with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Valsartan medicines, was published on 21 December 2021.

Levocetirizine: The consultation process for Levocetirizine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Levocetirizine medicines, was published on 26 October 2021.

Rosuvastatin/Ezetimibe: The consultation process for Rosuvastatin/Ezetimibe with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Rosuvastatin/Ezetimibe medicines, was published on 28 September 2021.

Venlafaxine: The consultation process for Venlafaxine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Venlafaxine medicines, was published on 05 September 2021.

Latanoprost: The consultation process for Latanoprost with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Latanoprost medicines, was published on 04 August 2021.

Ezetimibe/Simvastatin: The consultation process for Ezetimibe/Simvastatin:  with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Ezetimibe/Simvastatin medicines, was published on 27 July 2021.

Diclofenac: The consultation process for Diclofenac with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Diclofenac medicines, was published on 27 July 2021.

Losartan:
The consultation process for Losartan with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Losartan medicines, was published on 23 June 2021.

Ondansetron: The consultation process for Ondansetron with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Ondansetron medicines, was published on 23 June 2021.

Quetiapine:
The consultation Quetiapine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Quetiapine medicines, was published on 26 May 2021.

Memantine:
The consultation process for Memantine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Memantine medicines, was published on 19 May 2021.

Tamsulosin: The consultation process for Tamsulosin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Tamsulosin medicines, was published on 28 April 2021.

Emtricitabine/Tenofovir Disoproxil: The consultation process for Emtricitabine/Tenofovir Disoproxil with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Doxazosin medicines, was published on 13 April 2021.

 
Doxazosin: The consultation process for Doxazosin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Doxazosin medicines, was published on 17 February 2021.

Latanoprost: The consultation process for Latanoprost with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Latanoprost medicines, was published on 20 January 2021.

Pregabalin: The consultation process for Pregabalin with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Pregabalin medicines, was published on 20 January 2021.

Felodipine/Ramapril: The consultation process for Felodipine/Ramapril with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Felodipine/Ramapril medicines, was published on 20 January 2021.

Losartan: The consultation process for Losartan with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Losartan medicines, was published on 13 January 2021.


Ondansetron:
 The consultation process for Ondansetron with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Ondansetron medicines, was published on 23 December 2020.

Letrozole:
 The consultation process for Letrozole with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Letrozole medicines, was published on 04 November 2020.

Solifenacin succinate: The consultation process for Solifenacin succinate with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Solifenacin succinate medicines, was published on 27 June 2023.

Flucloxacillin: The consultation process for Flucloxacillin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Flucloxacillin medicines, was published on 28 October 2020.

Telmisartan:
The consultation process for Telmisartan with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Telmisartan medicines, was published on 15 October 2020.

Eplerenone:
The consultation process for Eplerenone with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Eplerenone medicines, was published on 09 September 2020.

Azithromycin:
The consultation process for Azithromycin with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Azithromycin medicines, was published on 09 September 2020.

Clopidogrel/Acetylsalicylic Acid:
The consultation process for Clopidogrel/Acetylsalicylic Acid with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Clopidogrel/Acetylsalicylic Acid medicines, was published on 02 September 2020.

Gabapentin:
The consultation process for Gabapentin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Gabapentin medicines, was published on 12 August 2020.

Solifenacin succinate/Tamsulosin:
The consultation process for Solifenacin succinate/Tamsulosin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Solifenacin succinate/Tamsulosin medicines, was published on 26th September 2023.

Sitagliptin/Metformin: 
The consultation process for Sitagliptin/Metformin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Sitagliptin/Meformin medicines, was published on 26th September 2023.

Tamsulosin: The consultation process for Tamsulosin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Tamsulosin medicines, was published on 17 June 2020.

Omeprazole:
The consultation process for Omeprazole with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Omeprazole medicines, was published on 03 June 2020.

Rasagiline: 
The consultation process for Rasagiline with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Rasagiline medicines, was published on 29 April 2020.

Nebivolol:
The consultation process for Nebivolol with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Nebivolol medicines, was published on 22 April 2020.

Atorvastatin:
The consultation process for Atorvastatin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Atorvastatin medicines, was published on 24 March 2020.

Salbutamol: The consultation process for Salbutamol with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Salbutamol medicines, was published on 22 January 2020.
 
Alprazolam: The consultation process for Alprazolam with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Alprazolam medicines, was published on 22 January 2020.

Sildenafil: The consultation process for Sildenafil with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Sildenafil medicines, was published on 18 December 2019.

Quetiapine:
 The consultation process for Quetiapine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Quetiapine medicines, was published on 04 December 2019. 

Gabapentin:
 The consultation process for Gabapentin with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Gabapentin medicines, was published on 03 December 2019. 

Pregabalin: The consultation process for Pregabalin with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Pregabalin medicines, was published on 03 December 2019. 

Rosuvastatin/Ezetimibe: The consultation process for Rosuvastatin/Ezetimibe with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Rosuvastatin/Ezetimibe medicines, was published on 21 November 2019. 

Tamsulosin: The consultation process for Tamsulosin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Tamsulosin medicines, was published on 13 November 2019. 

Telmisartan / Hydrochlorothiazide: The consultation process for Telmisartan / Hydrochlorothiazide with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Telmisartan / Hydrochlorothiazide medicines, was published on 01 November 2019. 

Emtricitabine Tenofovir disoproxil: The consultation process for Emtricitabine Tenofovir disoproxil with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Emtricitabine Tenofovir disoproxil medicines, was published on 30 October 2019.

Anastrozole: The consultation process for Anastrozole with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Anastrozole medicines, was published on 03 October 2019.

Metformin: The consultation process for Metformin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Metformin medicines, was published on 03 October 2019.

Alendronic Acid: The consultation process for Alendronic Acid with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Alendronic Acid medicines, was published on 11 September 2019

Simvastatin: The consultation process for Simvastatin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Simvastatin medicines, was published on 05 September 2019. 

Latanoprost: The consultation process for Latanoprost with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Latanoprost medicines, was published on 05 September 2019. 

Ezetimibe/Simvastatin: The consultation process for Ezetimibe/Simvastatin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable 
Ezetimibe/Simvastatin medicines, was published on 04 September 2019.

Gliclazide: The consultation process for Gliclazide with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Gliclazide medicines, was published on 28 August 2019.

Clarithromycin: The consultation process for Clarithromycin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Clarithromycin medicines, was published on 28 August 2019.

Etoricoxib: The consultation process for Etoricoxib with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Etoricoxib medicines, was published on 22 August 2019.

Olmesartan/Hydrochlorothiazide: The consultation process for Olmesartan/Hydrochlorothiazide with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Olmesartan/Hydrochlorothiazide medicines, was published on 15 August 2019.

Olmesartan: The consultation process for Olmesartan with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Olmesartan medicines, was published on 15 August 2019.

Clarithromycin: The consultation process for Clarithromycin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Clarithromycin medicines, was published on 07 August 2019.

Quetiapine: The consultation process for Quetiapine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Quetiapine medicines, was published on 24 July 2019.

Ezetimibe: 
The consultation process for Ezetimibe with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Ezetimibe medicines, was published on 11 July 2019.

Methotrexate: 
The consultation process for Methotrexate with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Methotrexate medicines, was published on 14 June 2019.

Risperidone: 
The consultation process for Risperidone with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Rosuvastatin medicines, was published on 13 June 2019.

Rosuvastatin: 
The consultation process for Rosuvastatin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Rosuvastatin medicines, was published on 08 May 2019.
 
Tramadol:
 The consultation process for Tramadol with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Tramadol medicines, was published on 08 May 2019.

Esomeprazole: 
The consultation process for Esomeprazole with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Esomeprazole medicines, was published on 01 May 2019.

Atorvastatin: 
The consultation process for Atorvastatin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Atorvastatin medicines, was published on 01 May 2019.

 

Salbutamol: The consultation process for Salbutamol with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Salbutamol medicines, was published on 30 April 2019.


Alendronic Acid:
The consultation process for Alendronic Acid with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Alendronic Acid medicines, was published on 10 April 2019.

Diclofenac Sodium:
The consultation process for Diclofenac Sodium with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Diclofenac Sodium medicines, was published on 20 February 2019.

Oxycodone/Naloxone: The consultation process for Oxycodone/Naloxone with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Oxycodone/Naloxone medicines, was published on 13 February 2019.

Quetiapine: The consultation process for Quetiapine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Quetiapine medicines, was published on 24 January 2019.

Rosuvastatin: The consultation process for Rosuvastatin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Rosuvastatin medicines, was published on 24 October 2018.

Omeprazole: The consultation process for Omeprazole with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Omeprazole medicines, was published on 05 October 2018.

Esomeprazole/Naproxen: The consultation process for Esomeprazole/Naproxen with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Esomeprazole/Naproxen medicines, was published on 19 September 2018.

Tramadol: The consultation process for Tramadol with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Tramadol medicines, was published on 02 August 2018.

Diclofenac: The consultation process for Diclofenac with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Diclofenac medicines, was published on 01 August 2018. 

Co-Amoxiclav: The consultation process for Co-Amoxiclav with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Co-Amoxiclav medicines, was published on 18 July 2018.

Latanoprost: The consultation process for Latanoprost with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Latanoprost medicines, was published on 11 July 2018.

Lactulose: The consultation process for Lactulose with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Lactulose medicines, was published on 27 June 2018.

Quetiapine: The consultation process for Quetiapine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Quetiapine medicines, was published on 07 June 2018.

Salbutamol: The consultation process for Salbutamol with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Salbutamol medicines, was published on 06 June 2018.

Duloxetine: The consultation process for Duloxetine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Duloxetine medicines, was published on 31 May 2018.

Levocetrizine: The consultation process for Levocetirizine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Levocetirizine medicines, was published on 30 May 2018.

Aripiprazole: The consultation process for Aripiprazole with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Aripiprazole medicines, was published on 30 May 2018.

Omeprazole: The consultation process for Omeprazole with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Omeprazole medicines, was published on 06 April 2018.

Rosuvastatin: The consultation process for Rosuvastatin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Rosuvastatin medicines, was published on 05 April 2018.

Esomeprazole: The consultation process for Esomeprazole with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Esomeprazole medicines, was published on 22 March 2018.

Nebivolol: The consultation process for Nebivolol with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Nebivolol medicines, was published on 8 March 2018.

Tramadol/Paracetamol: The consultation process for Tramadol/Paracetamol with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Tramadol/Paracetamol medicines, was published on 6 March 2018.

Atorvastatin: The consultation process for Atorvastatin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Atorvastatin medicines, was published on 6 March 2018.

Venlafaxine: The consultation process for Venlafaxine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Venlafaxine medicines, was published on 6 March 2018.

Amoxicillin/Clavulanic Acid: The consultation process for Amoxicillin/Clavulanic Acid with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Amoxicillin/Clavulanic Acid medicines, was published on 21 February 2018.

Clarithromycin: The consultation process for Clarithromycin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Clarithromycin medicines, was published on 6 December 2017.

Sildenafil: The consultation process for Sildenafil with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Sildenafil medicines, was published on 17 November 2017.

Tamsulosin: The consultation process for Tamsulosin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Tamsulosin medicines, was published on 25 October 2017.

Levocetirizine: The consultation process for Levocetirizine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Levocetirizine medicines, was published on 25 October 2017.

Flurazepam: The consultation process for Flurazepam with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Flurazepam medicines, was published on 18 October 2017.

Rosuvastatin: The consultation process for Rosuvastatin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Rosuvastatin medicines, was published on 04 October 2017.

Venlafaxine: The consultation process for Venlafaxine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Venlafaxine medicines, was published on 06 September 2017.

Risedronic Acid: The consultation process for Risedronic Acid with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Risedronic Acid medicines, was published on 23 August 2017.

Clopidogrel: The consultation process for Clopidogrel with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Clopidogrel medicines, was published on 10 August 2017.

Simvastatin: The consultation process for Simvastatin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Simvastatin medicines, was published on 25 July 2017.

Valsartan: The consultation process for Valsartan with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Valsartan medicines, was published on 29 June 2017.

Clarithromycin: The consultation process for Clarithromycin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Clarithromycin medicines, was published on 21 June 2017.

Citalopram: The consultation process for Citalopram with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Citalopram medicines, was published on 14 June 2017.

Pantoprazole: The consultation process for Pantoprazole with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Pantoprazole medicines, was published on 14 June 2017.

Methotrexate: The consultation process for Methotrexate with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Methotrexate medicines, was published on 31 May 2017.

Sildenafil: The consultation process for Sildenafil with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Sildenafil medicines, was published on 17 May 2017.

Donepezil: The consultation process for Donepezil with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Donepezil medicines, was published on 17 May 2017.

Lansoprazole: The consultation process for Lansoprazole with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Lansoprazole medicines, was published on 10 May 2017.

Rosuvastatin: The consultation process for Rosuvastatin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Rosuvastatin medicines, was published on 26 April 2017.

Valsartan: The consultation process for Valsartan with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Valsartan medicines, was published on 26 April 2017.

Levocetirizine: The consultation process for Levocetirizine with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Levocetirizine medicines, was published on 26 April 2017.

Omeprazole: The consultation process for Omeprazole with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Omeprazole medicines, was published on 19 April 2017.

Flucloxacillin: The consultation process for Flucloxacillin with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Flucloxacillin medicines, was published on 12 April 2017.

Ranitidine: The consultation process for Ranitidine with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Ranitidine medicines, was published on 05 April 2017.

Cetirizine: The consultation process for Cetirizine with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Cetirizine medicines, was published on 29 March 2017.

Betahistine: The consultation process for Betahistine with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Betahistine medicines, was published on 22 March 2017.

Domperidone: The consultation process for Domperidone with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Domperidone medicines, was published on 15 March 2017.

Tramadol/Paracetamol: The consultation process for Tramadol/Paracetamol with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Tramadol/Paracetamol medicines, was published on 15 March 2017.

Nebivolol: The consultation process for Nebivolol with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Nebivolol medicines, was published on 08 March 2017.

Tolterodine:
The consultation process for Tolterodine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Tolterodine medicines, was published on 22 February 2017.

Fluoxetine: The consultation process for Fluoxetine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Fluoxetine medicines, was published on 18 January 2017.

Quetiapine: The consultation process for Quetiapine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Quetiapine medicines, was published on 22 December 2016.

Gliclazide: The consultation process for Gliclazide with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Gliclazide medicines, was published on 21 December 2016.

Alendronic acid: The consultation process for Alendronic acid with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Alendronic acid medicines, was published on 21 December 2016.

Alprazolam: The consultation process for Alprazolam with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Alprazolam medicines, was published on 14 December 2016.

Duloxetine: The consultation process for Duloxetine with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Duloxetine medicines, was published on 07 December 2016.

Aripiprazole:
The consultation process for Aripiprazole with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Aripiprazole medicines, was published on 22 November 2016.

Metformin: The consultation process for Metformin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Metformin medicines, was published on 28 September 2016.

Valsartan: The consultation process for Valsartan with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Valsartan medicines, was published on 28 September 2016.

Amlodipine: The consultation process for Amlodipine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Amlodipine medicines, was published on 21 September 2016.

Telmisartan: The consultation process for Telmisartan with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Telmisartan medicines, was published on 14 September 2016.

Rosuvastatin: The consultation process for Rosuvastatin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Rosuvastatin medicines, was published on 14 September 2016.

Atorvastatin: The consultation process for Atorvastatin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Atorvastatin medicines, was published on 31 August 2016.

Tramadol/Paracetamol: The consultation process for Tramadol/Paracetamol with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Tramadol/Paracetamol medicines, was published on 31 August 2016.

Ramipril: The consultation process for Ramipril with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Ramipril medicines, was published on 06 July 2016.

Quetiapine: The consultation process for Quetiapine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Quetiapine medicines, was published on 29 June 2016.

Sertraline: The consultation process for Sertraline with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Sertraline medicines, was published on 29 June 2016.

Telmisartan: The consultation process for Telmisartan with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Telmisartan medicines, was published on 30 March 2016.

Rosuvastatin:
The consultation process for Rosuvastatin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Rosuvastatin medicines, was published on 23 March 2016.

​Amlodipine:
The consultation process for Amlodipine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Amlodipine medicines, was published on 23 March 2016.

Bisoprolol: The consultation process for Bisoprolol with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Bisoprolol medicines, was published on 24 February 2016.

Capecitabine: The consultation process for Capecitabine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Capecitabine medicines, was published on 03 February 2016.

Amoxicillin/Clavulanic acid: The consultation process for Amoxicillin/Clavulanic acid with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Amoxicillin/Clavulanic acid medicines, was published on 20 January 2016.

Lansoprazole: The consultation process for Lansoprazole with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Lansoprazole medicines, was published on 18 November 2015.

Alendronic acid: The consultation process for Alendronic acid with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Alendronic acid medicines, was published on 11 November 2015.

Risperidone: The consultation process for Risperidone with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Risperidone medicines, was published on 04 November 2015.

Rosuvastatin: The consultation process for Rosuvastatin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Rosuvastatin medicines, was published on 14 October 2015.

Escitalopram: The consultation process for Escitalopram with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Escitalopram medicines, was published on 07 October 2015.

Omeprazole: The consultation process for Omeprazole with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Omeprazole medicines, was published on 07 October 2015.

Amlodipine: The consultation process for Amlodipine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Amlodipine medicines, was published on 30 September 2015.

Diclofenac: The consultation process for Diclofenac with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Diclofenac medicines, was published on 30 September 2015.

Simvastatin: The consultation process for Simvastatin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Simvastatin medicines, was published on 23 September 2015.
 

Telmisartan: The consultation process for Telmisartan with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Telmisartan medicines, was published on 23 September 2015.

Venlafaxine: The consultation process for Venlafaxine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Venlafaxine medicines, was published on 16 September 2015.

Atorvastatin: The consultation process for Atorvastatin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Atorvastatin medicines, was published on 16 September 2015.

Clopidogrel:
 The consultation process for Clopidogrel with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Clopidogrel medicines, was published on 12 August 2015.

Anastrazole: The consultation process for Anastrazole with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Anastrazole medicines, was published on 12 August 2015.

Pantoprazole:
 The consultation process for Pantoprazole with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Pantoprazole medicines, was published on 29 July 2015.

Co-amoxiclav: 
The consultation process for Co-amoxiclav with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Co-amoxiclav medicines, was published on 03 July 2015.

Bisoprolol:
 The consultation process for Bisoprolol with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Bisoprolol medicines, was published on 17 June 2015.

Montelukast: The consultation process for Montelukast with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Montelukast medicines, was published on 10 June 2015.

Quetiapine: The consultation process for Quetiapine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Quetiapine medicines, was published on 03 June 2015.

Donepezil: The consultation process for Donepezil with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Donepezil medicines, was published on 27 May 2015.

Lansoprazole: The consultation process for lansoprazole with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Lansoprazole medicines, was published on 20 May 2015.

Pravastatin: The consultation process for Pravastatin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Pravastatin medicines, was published on 22 April 2015.

Escitalopram: The consultation process for Escitalopram with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Escitalopram medicines, was published on 01 October 2015.

Esomeprazole: The consultation process for Esomeprazole with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Esomeprazole medicines, was published on 19 March 2015.

Amlodipine: The consultation process for Amlodipine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Amlodipine medicines, was published on 19 March 2015.

Metformin: The consultation process for Metformin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Metformin medicines, was published on 19 March 2015.

Atorvastatin: The consultation process for Atorvastatin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Atorvastatin medicines, was published on 11 March 2015.

Losartan: The consultation process for Losartan with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Losartan medicines, was published on 4 March 2015.

Tramadol: The consultation process for Tramadol with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Tramadol medicines, was published on 18 February 2015.

Capecitabine: The consultation process for Capecitabine with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Capecitabine medicines, was published on 20 January 2015.

Temozolomide: The consultation process for Temozolomide with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Temozolomide medicines, was published on 20 January 2015.

Fluoxetine: The consultation process for Fluoxetine with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Fluoxetine medicines, was published on 18 December 2014.

Paroxetine:
The consultation process for Paroxetine with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Paroxetine medicines, was published on 17 December 2014.

Clarithromycin: The consultation process for Clarithromycin with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Clarithromycin medicines, was published on 10 December 2014.

Citalopram: The consultation process for Citalopram with the relevant marketing authorisation holders has been completed.  The initial list, including interchangeable Citalopram medicines, was published on 10 December 2014.

Alendronic acid: The consultation process for Alendronic acid with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Alendronic acid medicines, was published on 19 November 2014.

Tamsulosin: The consultation process for Tamsulosin with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Tamsulosin medicines, was published on 08 October 2014.

Telmisartan: The consultation process for Telmisartan with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Telmisartan medicines, was published on 04 September 2014.

Venlafaxine: The consultation process for Venlafaxine with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Venlafaxine medicines, was published on 27 August 2014.

Risedronic Acid: The consultation process for Risedronic Acid with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Risedronic Acid medicines, was published on 21 August 2014.

Zopiclone: The consultation process for Zopiclone with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Zopiclone medicines, was published on 07 August 2014.

Diclofenac: The consultation process for Diclofenac with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Diclofenac medicines, was published on 24 July 2014.

Doxazosin: The consultation process for Doxazosin with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Doxazosin medicines, was published on 10 July 2014.

Perindopril: The consultation process for Perindopril with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Perindopril medicines, was published on 10 July 2014.

Mirtazapine: The consultation process for Mirtazapine with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Mirtazapine medicines, was published on 08 July 2014.

Valsartan: The consultation process for Valsartan with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Valsartan medicines, was published on 27 June 2014.

Bisoprolol: The consultation process for Bisoprolol with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Bisoprolol medicines, was published on 19 June 2014.

Montelukast: The consultation process for Montelukast with the relevant marketing authorisation holders has been completed. The initial list, including interchangeable Montelukast medicines, was published on 29 May 2014.

Tolterodine: The consultation process for Tolterodine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Tolterodine medicines, was published on 25 February 2015.

Ramipril: The consultation process for Ramipril with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Ramipril medicines, was published on 20 January 2015.

Sertraline:
The consultation process for Sertraline with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Sertraline medicines, was published on 14 October 2014.

Sildenafil: The consultation process for Sildenafil with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Sildenafil medicines, was published on 26 November 2014.

Memantine: The consultation process for Memantine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Memantine medicines, was published on 19 November 2014.

Risperidone: The consultation process for Risperidone with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Risperidone medicines, was published on 14 October 2014.

Olanzapine: The consultation process for Olanzapine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Olanzapine medicines, was published on 09 October 2014.

Candesartan: The consultation process for Candesartan with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Candesartan medicines, was published on 05 Spetember 2014

Rabeprazole: The consultation process for Rabeprazole with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable rabeprazole medicines, was published on 18 August 2014.

Simvastatin: The consultation process for Simvastatin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Simvastatin medicines, was published on 23 May 2014.

Co-Amoxiclav: The consultation process for Co-Amoxiclav with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable Co-Amoxiclav medicines, was published on 15 October 2014.

Lercanidipine: The consultation process for lercanidipine with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable lercanidipine medicines, was published on 17 June 2014.

Pantoprazole: The consultation process for pantoprazole with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable pantoprazole medicines, was published on 18 December 2014.

Omeprazole: The consultation process for omeprazole with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable omeprazole medicines, was published on 07 October 2015.

Rosuvastatin: The consultation process for rosuvastatin with the relevant marketing authorisation holders has been completed. The amended list, including interchangeable rosuvastatin medicines, was published on 23 September 2014.